Business
Cleveland Diagnostics Names Jack Kenny as Chairman of the Board
CLEVELAND, February 05, 2026--Cleveland Diagnostics Names Jack Kenny as Chairman of the Board
About this update from Danaher Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":650,"height":231,"url":"https://media.zenfs.com/en/business-wire.com/d4fc80c91208a724496e5c387d2ea4dc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GAm6vTq2BtGLN8cW8BecTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d4fc80c91208a724496e5c387d2ea4dc","width":650,"height":231},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/9W__hT4hS2FpK9KWFPnt0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIyNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d4fc80c91208a724496e5c387d2ea4dc","width":640,"height":227}},"lazy":false},{"type":"text","content":"Seasoned industry executive brings proven leadership to support commercial scale of IsoPSA® Assay & platform expansion","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"CLEVELAND, February 05, 2026--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, today announced the appointment of Jack Kenny as Chairman of the Board of Directors. Kenny joins the company at a pivotal time as Cleveland Diagnostics accelerates commercial growth following recent FDA approval of its IsoPSA® IVD Assay and expands its broader IsoClear™ platform.","length":415,"tagName":"p"},{"type":"text","content":"Kenny brings more than three decades of operational, commercial, and board-level leadership experience across the diagnostics and life sciences industries. He has deep expertise in the in vitro diagnostics, molecular, and laboratory services sectors. Most recently, he served as Chief Executive Officer of Meridian Bioscience. His prior leadership roles include senior executive positions at Siemens Healthcare, Becton Dickinson Diagnostics, Danaher, and Quest Diagnostics, as well as current and past board service across both public and private organizations.","length":561,"tagName":"p"},{"type":"text","content":""Cleveland Diagnostics is entering a defining phase of growth," said Kenny. "I’m excited to join the board at this moment and work closely with the leadership team to help scale the business to expand access to IsoPSA and support a platform that has the potential to extend well beyond prostate cancer."","length":323,"tagName":"p"}...